| Patents for A61K 49 - Preparations for testing in vivo (35,376) |
|---|
| 01/06/2005 | WO2005000271A1 Method for improving stability and shelf-life of liposome complexes |
| 01/06/2005 | WO2005000218A2 Macrocyclic cyanine and indocyanine bioconjugates provide improved biomedical applications |
| 01/06/2005 | WO2005000109A2 Quaternary nitrogen heterocyclic compounds for detecting aqueous monosaccharides in physiological fluids |
| 01/06/2005 | WO2004082722A3 Radiolabeled conjugates based on substance p and the uses thereof |
| 01/06/2005 | WO2004064751A3 Nanoparticle based stabilization of ir fluorescent dyes |
| 01/06/2005 | WO2003088913A8 Peptide deformylase activated prodrugs |
| 01/06/2005 | US20050004196 Treatment and prevention of inflammation and associated diseases |
| 01/06/2005 | US20050004026 Induction of capacse cascade ; administering apoptosis inducing protein; drug screening; anticancer agents |
| 01/06/2005 | US20050003467 Such as epiephrine which is contacted with blood vessel that feeds nutrients to tumor tissue, and hemolyzing red blood cells; drug screening |
| 01/06/2005 | US20050003448 Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| 01/06/2005 | US20050003021 Bowel cleansing agent |
| 01/06/2005 | US20050002998 Method for improving stability and shelf-life of liposome complexes |
| 01/06/2005 | US20050002904 Uses of vascular endothelial growth factor and type I collagen inducible protein (VCIP) |
| 01/06/2005 | US20050002866 Contrast agent containing gadolinium chelate compound |
| 01/06/2005 | US20050002865 Diagnostic/therapeutic agents |
| 01/06/2005 | US20050002864 1,3-glyceride compound having two iodophenyl groups |
| 01/06/2005 | US20050002863 Method for assessing food palatability and preference in animals using a cognitive palatability assessment protocol |
| 01/06/2005 | US20050002859 COX-2-targeted imaging agents |
| 01/06/2005 | CA2530408A1 Cox-2-targeted imaging agents |
| 01/06/2005 | CA2526760A1 Optically pure and enriched isomers of chelating ligands and contrast agents |
| 01/05/2005 | EP1493439A1 Means of ascertaining an individual' s risk profile for atherosclerotic disease |
| 01/05/2005 | EP1492776A2 Iodinated triglyceride analogs |
| 01/05/2005 | EP1492570A2 Method of diagnosis and treatment of breast lesions |
| 01/05/2005 | EP1492554A2 Spherical protein particles and methods of making and using them |
| 01/05/2005 | EP1492452A2 System, formulation, kit and method for tagging colonic residue in an individual |
| 01/05/2005 | DE10324365A1 Vorrichtung mit einer Räumlichkeit zur Aufnahme von hyperpolarisiertem Edelgas Device with a space for receiving hyperpolarized noble gas |
| 01/05/2005 | CN2668069Y 二氧化碳气体储存和释放装置 Carbon dioxide gas storage and release device |
| 01/05/2005 | CN1561246A Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease |
| 01/05/2005 | CN1559615A Location controlled releasing method for ultrasonic microbubble contrast medium |
| 01/05/2005 | CN1182876C Methods for detecting lesions in dense tissue using LHRH antagonists |
| 01/05/2005 | CN1182875C Method for mixing contrast medium contaniing gas and irrigating medium by continuous infusion before administration |
| 01/05/2005 | CN1182870C Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations |
| 01/04/2005 | US6838273 Cloning and characterization of the FLBA gene of H. pylori, production of aflagellate strains |
| 01/04/2005 | US6838074 Tumor imaging; kits |
| 12/30/2004 | US20040265972 Modified human chorionic gonadotropin (CG) for use in treatment and prevention of metabolic and reproductive diseases |
| 12/30/2004 | US20040265896 pharmacogenetics; determining if patient has said variant which causes sensitivity to ivermectin and other drugs that serve as P-glycoprotein substrates; canine cell used for studying effect of various drugs |
| 12/30/2004 | US20040265879 peptide nucleic acid conjugate of a nucleic acid analog covalently linked to a peptide transporter moiety; enhance antisense activity; drug delivery; conjugate is a morpholino-base with phosphorodiamidate linkages with a peptide such as Arg9Phe2 (arginine9phenylalanine2) |
| 12/30/2004 | US20040265824 Secreted and cell surface genes expressed in benign and malignant colorectal tumors |
| 12/30/2004 | US20040265393 Non-invasive intravascular thrombolysis using modified ultrasound techniques |
| 12/30/2004 | US20040265392 Nanoparticles comprising biologically active tnf which is immobilized on the same |
| 12/30/2004 | US20040265350 Ceramic carrier comprising interconnected skeleton of scaffolding and struts having pores; low density; time-release agents; fibroblast-, or transforming growth factors; bone morphogenic proteins, somatotrophin; antibiotics, vitamins, proteins, hormones, radiopacity agents |
| 12/30/2004 | US20040265308 Prevention and treatment of amyloidogenic disease |
| 12/30/2004 | US20040265236 Trimeric macrocyclic substituted benzene derivatives |
| 12/30/2004 | US20040265235 extended poly(amino acid) conjugated to chelator moieties that form coordination complexes with paramagnetic ions |
| 12/30/2004 | US20040265229 Urokinase plasminogen activator receptor as a target for diagnosis of metastases |
| 12/30/2004 | DE10325752A1 Lektin-Konjugate Lectin conjugates |
| 12/29/2004 | WO2004113270A2 Propionic acid derivatives useful in the treatment of lipid disorders |
| 12/29/2004 | WO2004112840A2 Peptide conjugate for magnetic resonance imaging |
| 12/29/2004 | WO2004112839A2 Specific high-relaxivity conjugate compounds for magnetic resonance imaging |
| 12/29/2004 | WO2004112834A1 Cancerous disease modifying antibodies |
| 12/29/2004 | WO2004112763A2 Inhibition of protein kinase c-mu (pkd) as a treatment for cardiac hypertrophy and heart failure |
| 12/29/2004 | WO2004112590A2 Methods of enhancing radiation effects with metal nanoparticles |
| 12/29/2004 | WO2004112563A2 Gastrointestinal methods and apparatus for use in treating disorders |
| 12/29/2004 | WO2004112473A1 Novel animal model for epilepsy |
| 12/29/2004 | WO2004100769A3 Methods for using gadolinium as a contrast media |
| 12/29/2004 | WO2004096152A3 In situ gelling self-reactive materials for embolization |
| 12/29/2004 | WO2004096124A3 Compositions and methods for the diagnosis and treatment of tumor |
| 12/29/2004 | WO2004061410A3 Serum biomarkers in lung cancer |
| 12/29/2004 | WO2004015072A3 Mrbs as modifiers of the rb pathway and methods of use |
| 12/29/2004 | EP1491208A1 Stabilized liquid polypeptide-containing pharmaceutical compositions |
| 12/29/2004 | EP1491147A1 Device and method for safe location and marking of a cavity and sentinel lymph nodes |
| 12/29/2004 | EP1490120A1 Embolization |
| 12/29/2004 | EP1490084A2 Compositions and methods for regulating thyroid hormone metabolism and cholesterol and lipid metabolism via the nuclear receptor car |
| 12/29/2004 | EP1490032A1 Processes for manufacturing polymeric microspheres |
| 12/29/2004 | EP1489971A2 Methods for ultrasonic imaging and treating diseased tissues |
| 12/29/2004 | EP1289562B1 Novel preparation of hypericin bonded with poly-n-vinylamides |
| 12/29/2004 | EP1218037B1 In vivo assay for testing the phenotypic stability |
| 12/29/2004 | EP1210069B1 Large porous particles obtainable by spray-drying and suitable for pulmonary administration |
| 12/29/2004 | EP1028757B1 Radioactive embolizing compositions |
| 12/29/2004 | CN1557496A Intussusception reposition developer under ultrasonic aid and its preparing process |
| 12/29/2004 | CA2530214A1 Cancerous disease modifying antibodies |
| 12/29/2004 | CA2528234A1 Propionic acid derivatives useful in the treatment of lipid disorders |
| 12/29/2004 | CA2526423A1 Inhibition of protein kinase c-mu (pkd) as a treatment for cardiac hypertrophy and heart failure |
| 12/28/2004 | US6835549 Immunoassay method for the diagnosis of gastric intestinal metaplasia associated with gastric carcinoma |
| 12/28/2004 | US6835370 Diagnosis and treatment of malignant neoplasms |
| 12/28/2004 | CA2143805C Process for the preparation and purification of iodinated contrast agents |
| 12/23/2004 | WO2004110963A2 Glycerophosphocholine and its derivatives for medical imaging neuropsychiatric disorders |
| 12/23/2004 | WO2004110500A1 Radioactively labelled amino acid analogues, their preparation and use |
| 12/23/2004 | WO2004110373A2 Therapeutic vaccine compositions for the treatment of type 1 diabetes |
| 12/23/2004 | WO2004110339A2 Method for selective targeting of apoptotic cells and small molecule ligands used thereof |
| 12/23/2004 | WO2004110279A1 Blood flow estimates through replenishment curve fitting in ultrasound contrast imaging |
| 12/23/2004 | WO2004110255A2 Antineoplastic agents targeted via glut transporters |
| 12/23/2004 | WO2004110250A2 Diagnostic method for atherosclerosis |
| 12/23/2004 | WO2004080416A3 Animal model simulating neurologic disease |
| 12/23/2004 | WO2004041213A3 Methods for the identification of agents that modulate the structure and processing of beta-amyloid precursor protein |
| 12/23/2004 | WO2003089898A3 Determining biochemical markers of progression and therapy monitoring and specification, therapeutic lead molecules, and target biochemical systems applied to stroke |
| 12/23/2004 | WO2003083436A3 Fibrinogen binding moieties |
| 12/23/2004 | US20040260058 Point mutations, deletions; quantitative/qualitative analysis; immunoassay; blot analysis; drug screening |
| 12/23/2004 | US20040259158 PYK2 and inflammation |
| 12/23/2004 | US20040258761 Dissolving a biocompatible, biodegradable polymer in solution comprising sublimable substance and an oil phase; emulsification, pouring into surfactant solution to breaking; shrinkage, washing; enhancement during ultrasound; tumors |
| 12/23/2004 | US20040258760 Isolated nanocapsule populations and surfactant-stabilized microcapsules and nanocapsules for diagnostic imaging and drug delivery and methods for their production |
| 12/23/2004 | US20040258759 Forming image of sample and coated microparticle mixture by exposing to electromagnetic radiation of infrared or ultraviolet frequency; optical coherence tomography, holography, endoscopy; light, confocal, polarization, interference, and/ormulti-photon microscopy |
| 12/23/2004 | US20040258744 Surface modified lipoprotein-like oil in water emulsion having lipophilic core surrounded by monolayer of amphiphilic or polar lipids; polyoxyethylene glycol linked lipid and (choles)terol; radioactive or stable, synthetic polyhalogenated triglycerides as contrast agents; radiographic imaging |
| 12/23/2004 | US20040258620 In vivo stability, biocompatibility, organ specificity; low dosage, rapid excretion; nuclear magnetic resonance diagnostic imaging, radiotherapy |
| 12/23/2004 | US20040258619 Diaminedioxime radiometal complexes |
| 12/23/2004 | US20040258618 Magnetic resonance imaging of substrate molecule different from water; shortening relaxation times; in vivo mapping citrate; tumors |
| 12/23/2004 | US20040258617 Adding markers to lethal drugs for identification in body fluids and tissues; forensics |
| 12/23/2004 | US20040255757 Genetic music |
| 12/23/2004 | CA2529486A1 Method for selective targeting of apoptotic cells and small molecule ligands used thereof |
| 12/23/2004 | CA2527830A1 Therapeutic vaccine compositions for the treatment of type 1 diabetes |